Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first...

CASGEVY is a one-time therapy used to treat people aged 12 years and older with: sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs. beta thalassemia (β-thalassemia) who need regular blood transfusions

Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [3] [5] and transfusion-dependent beta thalassemia. [3] It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics. [9]

CASGEVY indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs).

CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso ...

CASGEVY is a one-time* gene therapy that may help people 12 years and older with sickle cell disease (SCD) and frequent vaso-occlusive crises (VOCs) live severe VOC-free. CASGEVY uses your own blood stem cells to help your body make working red …

2023年12月15日 · Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older. For beta thalassaemia, Casgevy is used in patients who require regular blood transfusions.

Discover CASGEVY (exagamglogene autotemcel): a first-of-its-kind, CRISPR/Cas9-modified cellular gene therapy. INDICATION. CASGEVY is indicated for the treatment of patients aged 12 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) transfusion-dependent β-thalassemia (TDT) IMPORTANT SAFETY INFORMATION

Casgevy, the first FDA-approved CRISPR/Cas9 gene therapy for sickle cell disease (SCD), offers a curative approach and eliminates the need for recurrent transfusions and transplants, thereby significantly enhancing the quality of life of individuals with SCD.

Casgevy (exagamglogene autotemcel) is a gene therapy that is given as a one-time intravenous infusion to treat adults and children aged 12 years and older with: Sickle cell disease with recurrent vaso-occlusive crises (VOCs). Transfusion-dependent β-thalassemia (TDT).